A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults - VICTORIA

Study identifier:D8111C00010

ClinicalTrials.gov identifier:NCT05057897

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase IV Open-Label, Non-Randomized, Multi-Cohort, Multicenter Study in Previously Unvaccinated Immunocompromised Adults to Determine the Immunogenicity and Safety of AZD1222 Vaccine for the Prevention of COVID-19

Medical condition

COVID-19, SARS-CoV-2

Phase

Phase 4

Healthy volunteers

Yes

Study drug

-

Sex

All

Actual Enrollment

34

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 31 Jan 2022
Primary Completion Date: 19 Apr 2023
Study Completion Date: 19 Apr 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Prevention

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria